

3010 Rec'd PCT/PTO 02 JAN 2000


FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <b>TRANSMITTAL LETTER TO THE UNITED STATES          DESIGNATED/ELECTED OFFICE (DO/EO/US)          CONCERNING A FILING UNDER 35 U.S.C. 371</b>		ATTORNEY'S DOCKET NUMBER  50159-026  U.S. APPLIC. NO. (if known, see 37 CFR 1.5) <b>10/019651</b>
INTERNATIONAL APPLICATION NO  PCT/SE00/01449	INTERNATIONAL FILING DATE  July 6, 2000	PRIORITY DATE CLAIMED  July 6, 1999
TITLE OF INVENTION  BIOSENSOR		
APPLICANTS FOR DO/EO/US  Elisabeth CSOREGI, Mihaela NICULESCU and Ivo FREBORT		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.		
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau)</li> <li>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. (A copy of the Published International Application is enclosed)</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</li> </ol> </li> <li>6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2))</li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> have been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendment has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3))</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input checked="" type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5))</li> </ol>		
<b>Items 11. to 16. below concern other document(s) or information included:</b>		
<ol style="list-style-type: none"> <li>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98</li> <li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment  <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment</li> <li>14. <input type="checkbox"/> A substitute specification</li> <li>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>16. <input checked="" type="checkbox"/> Other items or information.           <ol style="list-style-type: none"> <li>1. International Search Report prepared by the Swedish Patent Office.</li> <li>2. International Preliminary Examination Report.</li> <li>3. PCT Request</li> <li>4. Amended Pages 2 and 3</li> <li>5. Amendments to the claims under PCT Article 19.</li> <li>6. <b>APPLICANT IS ENTITLED TO CLAIM SMALL ENTITY STATUS.</b></li> </ol> </li> </ol>		



20277

PATENT TRADEMARK OFFICE

531 Rec'd PCT 10-2 JAN 2002

U.S. APPLIC. NO. (if known, see 37 CFR 1.50) <b>10/019651</b>		INTERNATIONAL APPLICATION NO. PCT/SE00/01449		ATTORNEY'S DOCKET NUMBER 50159-026	
				CALCULATIONS	PTO USE ONLY
17. <input checked="" type="checkbox"/> The following fees are submitted:					
<b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b> Search Report has been prepared by the EPO or JPO \$890.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) \$710.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$740.00  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,040.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 1,040.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e))				\$ 130.00	
Claims	Number Filed	Number Extra	Rate		
Total Claims	20 -20 =	0	x \$18.00	\$0.00	
Independent Claims	1 -3 =		x \$84.00	\$ 0.00	
Multiple dependent claim(s) (if applicable)			+ \$280.00	\$ 280.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,450.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$ 725.00	
SUBTOTAL =				\$ 725.00	
Processing fee of \$130.00 for furnishing the English translation later than the <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 0.00	
TOTAL NATIONAL FEE =				\$ 725.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$ 0.00	
TOTAL FEES ENCLOSED =				\$725.00	
				Amount to be: refunded	\$
				charged	\$ 725.00
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>500417</u> in the amount of \$ <u>725.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>500417</u> . A duplicate copy of this sheet is enclosed.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO:					
Robert L. Price McDERMOTT, WILL & EMERY 600 13 <sup>th</sup> Street, N.W. Washington, DC 20005-3096 (202) 756-8000					
SIGNATURE  Robert L. Price NAME 22,685 REGISTRATION NUMBER January 2, 2002					

Docket No.: 50159-026

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of :  
Elisabeth CSOREGI, et al. :  
Serial No.: : Group Art Unit:  
Filed: January 02, 2002 : Examiner:  
For: BIOSENSOR :

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

Prior to examination of the above-referenced application, please amend the application as follows:

**IN THE CLAIMS:**

Please amend the claims are follows:

4. (Amended) The biosensor according to claim 1, characterised in that the mono-enzyme or the bi-enzyme system is crosslinked into an osmium based redox polymer.

6. (Amended) The biosensor according to claim 1, characterised in that the biosensor is of Type I, Type II or Type III type of biosensor, wherein

Type I: the mono-enzyme or the bi-enzyme system is added direct on to the electrode surface; or

Type II: the mono-enzyme or the bi-enzyme system is entrapped in the osmium based redox polymer added on the top of the electrode; or

Type III: the mono-enzyme or the bi-enzyme system and the osmium based redox polymer forms sequential coatings added on top of the electrode.

8. (Amended) The biosensor according to claim 1, characterised in that the electrode is of noble metals, such as gold, silver, platinum, palladium, or carbon/graphite-based material, such as graphite, carbon pasted, vitrous carbon, carbon fibers, or conducting salts, or conducting polymers

10. (Amended) Use of the biosensor according to claim 1, as an analytical instrument or tool for the detection or determination of freshness biomarkers or of the content of freshness biomarkers in food, such as meat from animals or fishes, or beverages.

11. (Amended) Use of the biosensor according to claim 1, as an analytical instrument or tool for the detection or determination of biogenic amines, preferably histamine, in body fluids, such as blood, urine, saliva, sweat, in medical diagnoses or in the treatment of disease.

12. (Amended) Use of the biosensor according to claim 1 as an analytical instrument or tool for the detection or determination of biogenic amines, preferable histamine, in microdialysates or dialysates.

REMARKS

The above-referenced application is amended to delete the multiple dependency of claims 4, 6, 8, and 10 - 12. Attached is a marked-up version of the amended claims. Entry of this Preliminary Amendment is respectfully requested.

Respectfully submitted,

MCDERMOTT, WILL & EMERY



Robert L. Price

Registration No. 22,685

600 13<sup>th</sup> Street, N.W.  
Washington, DC 20005-3096  
(202)756-8000 RLP:kjw  
Facsimile: (202)756-8087  
**Date: May 2, 2002**

**MARKED-UP VERSION OF CLAIMS 4, 6, 8, 10 –12**

**IN THE CLAIMS:**

Please amend the claims are follows:

4. (Amended) The biosensor according to [any of the preceding] claim[s] 1, characterised in that the mono-enzyme or the bi-enzyme system is crosslinked into an osmium based redox polymer.

6. (Amended) The biosensor according to [any of the preceding] claim[s] 1, characterised in that the biosensor is of Type I, Type II or Type III type of biosensor, wherein

Type I: the mono-enzyme or the bi-enzyme system is added direct on to the electrode surface; or

Type II: the mono-enzyme or the bi-enzyme system is entrapped in the osmium based redox polymer added on the top of the electrode; or

Type III: the mono-enzyme or the bi-enzyme system and the osmium based redox polymer forms sequential coatings added on top of the electrode.

8. (Amended) The biosensor according to [any of the preceding] claim[s] 1, characterised in that the electrode is of noble metals, such as gold, silver, platinum, palladium, or carbon/graphite-based material, such a graphite, carbon pasted, vitrous carbon, carbon fibers, or conducting salts, or conducting polymers

10. (Amended) Use of the biosensor according to [any of] claim[s] 1 [to 9], as an analytical instrument or tool for the detection or determination of freshness biomarkers or of the content of freshness biomarkers in food, such as meat from animals or fishes, or beverages.

11. (Amended) Use of the biosensor according to [any of] claim[s] 1 [to 9], as an analytical instrument or tool for the detection or determination of biogenic amines, preferably histamine, in body fluids, such as blood, urine, saliva, sweat, in medical diagnoses or in the treatment of disease.

12. (Amended) Use of the biosensor according [any of] claim[s] 1 [to 9], as an analytical instrument or tool for the detection or determination of biogenic amines, preferable histamine, in microdialysates or dialysates.

10/019651

531 Rec'd PCH 02 JAN 2002

## PATENT

In re Application of	:	
	:	
Elisabeth CSÖREGI et al.	:	
	:	
Serial No.:	:	Group Art Unit:
	:	
Filed: January 02, 2002	:	Examiner:
	:	
For: BIOSENSOR	:	

Commissioner for Patents  
Washington, DC 20231

Prior to examination of the above-referenced application, please amend the application as follows:

Please replace the attached amended pages 2 and 3 of the specification with the pages as filed.

Please replace the attached amended sheets of claims 1-12, under PCT Article 19, with the original claims 1-14 as filed.




REMARKS

The above-referenced application has been amended to replace the amended pages 2 and 3 with the pages as filed and replace the claims as amended under PCT Article 19, with the original claims as filed. Attached hereto is a clean copy of the amended pages and replacement pages of claims. Entry of this preliminary amendment is respectfully requested.

Respectfully submitted,

MCDERMOTT, WILL & EMERY

 (#44,488)  
for Robert L. Price  
Registration No. 22,685

600 13<sup>th</sup> Street, N.W.  
Washington, DC 20005-3096  
(202) 756-8000 RLP:prp  
**Date: January 2, 2002**  
Facsimile: (202) 756-8087

10/019651

531 Rec'd PCT/PT 02 JAN 2002

BIOSENSOR

The present invention relates to a biosensor, which includes an electrode and a mono-enzyme- or a bi-enzyme-system and uses of  
5 the biosensor.

## BACKGROUND OF THE INVENTION

Rapid evaluation of food and beverage, such as fish, meat, quality is required in food industry. The biogenic amine content in food has been intensively studied because of their potential toxicity. Histamine is the most biologically active compound from this class, affecting the normal functions of the heart, smooth muscle, motor neurones, and gastric acid secretion. Other biogenic amines, such as putrescine and cadaverine,  
10 may amplify the effects caused by histamine intoxication, inhibiting the enzymes involved in histamine biodegradation: diamine oxidase and histamine-N-methyl transferase.

Numerous countries adopted maximum levels for histamine in food, especially in fish products. The Italian law has fixed a level of 100 mg/kg food, and similar limits have been adopted by EEC regulations.

Therefore, there is a need for developing of simple and inexpensive methods for determining of freshness biomarkers. Freshness biomarkers comprising inositol monophosphate, hypoxanthine and xanthine, these are intermediate degradation products of nucleic acids or biogenic amines, which are produced by microbial decarboxylation of the amino acids, histidine, ornithine,  
25 and lysine.

Classical methods for the determination of the content of biogenic amines are chromatographic techniques, such as gas chromatography, thin layer chromatography, reversed phase liquid chromatography, and liquid chromatography. However, these often  
35 require sample pre-treatment and relatively long analysing time, which leads to high costs and make these methods not suitable for routine use.

-2-

From US 5,565,329 is a method for determination of histamine concentration in a sample by determination of the decrease in dissolved oxygen (DO) known. The method involves adding a solution of an enzymatic reagent, which have a histamine oxidase activity, into an examination liquid containing the test sample and detect the sensor output signal. The analyser has a reaction cell provided with a DO electrode. The enzymatic reagent is a Cu-containing fungal amine oxidase. Which is extracted from a cellmass belonging to *Aspergillus Niger* cultured in a culture medium including amine as a nitrogen source. This approach is not very selective and sensitive.

Enzymatic determination of biogenic amines represents an alternative that can solve the above mentioned problems. However, most of the amino oxidase biosensors require a high operating potential (>500 mV vs. Ag/AgCl), which can lead to high background currents and low selectivity due to bias signals caused by electrochemically easily oxidisable interferences, which are always present in complex matrices, such as food or beverage.

#### SUMMARY OF THE INVENTION

As is clear from the description above a rapid, accurate, simple and handy analytical instrumental tool is needed for determination of food hygiene all along the food process line, starting from the source to the consumer.

With the present invention the above mentioned problems have been solved, the present invention offers a highly sensitive, selective rapid and very convenient determination and/or detection of the biomarkers in very small amounts.

Thus, the present invention relates to a biosensor for detection and/or determination of the content of freshness biomarkers in food or beverage. The biosensor comprises an electrode and a copper-containing amine oxidase derived from grass pea (AO, E. C. 1.4.3.6) in a mono-enzyme system, or in a bi-enzyme system containing said amine oxidase coupled with a peroxidase.

The mono-enzyme system comprising said copper containing amine oxidase (AO) represents one preferred embodiment of the invention. The amine oxidase may be isolated from grass pea and purified according to Šebela, M., et al, Phytochem. Anal. 1998, 9, 211-222.

Another preferred embodiment of the present invention is the biosensor comprising the bi-enzyme system comprising said copper containing amine oxidase (AO) coupled with a peroxidase (PO) such as horseradish (HRP), soybean, tobacco, sweet potato or palmtree peroxidase.

In another preferred embodiment of the present invention the mono-enzyme- or the bi-enzyme- system is crosslinked into an osmium redox polymer. The osmium-based redox polymer is preferably (PVI<sub>13</sub>-dmeOs) of poly- (1-vinyl-imidazole), complexed with [Os- (4,4'-dimethylbipyridine)<sub>2</sub> Cl]<sup>+2+</sup>, and a crosslinking agent such as poly-(ethyleneglycol)-diglycidyl-ether (PEGDGE).


Yet another embodiment of the present invention is the use of the biosensor as an analytical tool in the determination and/or detection of the freshness biomarkers in food.

Other uses and preferred embodiments of the present invention are defined in the use-claims and the subclaims.

#### DETAILED DESCRIPTION OF THE INVENTION

Amine oxidase represents a class of enzymes with a ubiquitous distribution in mammals, plants and micro-organisms. However, the structure, selectivity and biological functions are very different, depending on the isolation source. Grass-pea amine oxidase, for instance, is a copper-containing amino oxidase, which besides the metal ions also contains an organic cofactor with a quinoide structure (topa-quinone) in its catalytic site.

In methods, where an amine oxidase is used, the enzyme is converting the amine to the corresponding aldehyde, with NH<sub>3</sub> and H<sub>2</sub>O<sub>2</sub> release, according to reaction I



Both oxygen consumption and hydrogen peroxide formation have  
5 been used for monitoring of biogenic amines on the basis of the  
above mentioned reaction.

It has surprisingly been shown that the interaction between the  
material of the electrode and the enzyme(s) resulted in a very  
10 selective and sensitive biosensor. The electrode has to be of  
any electron conducting material, such as noble metals, car-  
bon/graphite-based material, conducting salts, conducting poly-  
mers etc.

15 The mono-enzyme based biosensor according to the present inven-  
tion is based either on the amine oxidase immobilised on top of  
an electrode (DET, direct electron transfer mechanism) or on  
amine oxidase crosslinked into a redox hydrogel forming a coat-  
ing layer on top of an electrode (MET, mediated electron trans-  
20 fer mechanism).


According to the bi-enzymatic approach of the invention, the  
bi-enzyme electrode configuration is based on the enzyme amine  
oxidase (AO), from grass pea, and horseradish peroxidase (HRP)  
25 on a solid graphite electrode. The bi-enzymatic system is work-  
ing at a potential where biases are minimal. The bi-enzyme  
electrodes were prepared either by simply adsorbing the two  
enzymes on the electrode surface (DET) or by crosslinking them  
into a redox polymer (MET). In the latter case the highly per-  
30 meable and stable redox hydrogel is formed of a poly(1 -  
vinylimidazole) complexed with  $[\text{Os}(4,4'\text{-dimethyl-}$   
 $\text{bipyridine})_2\text{Cl}]^{+/2+}$  (PV<sub>13</sub>-dmeOs) and crosslinked to the enzymes  
by a crosslinking agent e.g. poly-(ethylene-glycol)-diglycidyl-  
ether (PEGDGE).

35

The optimal biosensor design was evaluated in terms of sensi-  
tivity, selectivity, life- and response-time, and it was used  
for the analysis of fish samples stored under different condi-


tions.

In the DET reaction mechanism, the biosensor of the present invention amine oxidase first converts the amine substrate (e.g. histamine) to an aldehyde product, the active form of the enzyme being recovered by oxidation of the organic cofactor in presence of molecular oxygen according to reaction mechanism II:




Then the active form of the enzyme being recovered by oxidation of the organic cofactor in presence of molecular oxygen, see mechanism II. The hydrogen peroxide formed during the first reaction is subsequently reduced to water by the action of peroxidase. The native form of the second enzyme is re-made either by direct reduction of its heme cofactor on the electrode surface or by receiving electrons from a mediator, maintained in its reduced form by the potential applied on the graphite electrode (50 mV vs. Ag/AgCl).

The peroxidase is either reduced by direct reduction of its heme cofactor (reaction mechanism II) or by receiving electrons from a mediator (MET), such as an osmium based redox polymer (see reaction mechanism III), maintained in its reduced form by the potential applied.



Redox hydro-gels are an effective matrix for enzyme immobilisation resulting in increased stability and the enhanced rates of the electron transfer. The rate of the electron transfer is highly influenced by the composition of the redox hydrogel, as well as by the kinetics of the used enzyme(s). Therefore various biosensor designs were considered in order to find the optimal electrode structure displaying the most efficient rate of electron transfer.

The structure of the redox polymer [Os(4,4'-dimethyl-bipyridine)<sub>2</sub>Cl complexed to poly(1-vinyl-imidazole)] is shown in the following formula:



The mono-enzyme- or the bi-enzyme- system is applied on to the electrode in three different ways (type I, II and III). In the following, enzyme means mono-enzyme- or bi-enzyme- system if not otherwise is stated.

Biosensor Type I: the enzyme is applied direct on to the electrode surface (DET). The reaction follows reaction mechanism II.

Biosensor Type II: the enzyme is entrapped in a redox hydrogel and applied on the top of the electrode (MET, one layer electrode). The reaction follows reaction mechanism III.

Biosensor Type III: represent a sequential coating procedure of enzyme and redox polymer (MET, bilayer electrode). The reaction

follows also reaction mechanism III.

In order to achieve an effective electron transfer all types of biosensors were optimised with regard to amount of immobilised enzyme and ratio of the used enzyme (Type I), composition of enzymes : redox polymer : crosslinking agent (Type II) and influence of electrode coating procedures (Type III).

#### PREPARATION OF BIOSENSORS

The biosensors were prepared by modifying graphite electrodes, which were prepared as follows:

i) Rods of spectroscopic graphite (Ringsdorff Werke GmbH, Bonn, Germany, type RW001, 3.05 mm diameter) were cut, and polished on a wet fine emery paper (Tufback, Durite P1200, Allar, Sterling Heights, MI).

ii) The electrode surface was rinsed with water, dried at room temperature before coating with the enzymes. Three different electrode types were prepared:

Type I electrodes: were prepared by placing 6 µl of a premixed solution containing various amounts of AO (stock 20 mg/ml in phosphate buffer 0.1 M, pH 7.2 (PB)) and HRP (stock 10 mg/ml in PB) on the graphite electrode.

Type II electrodes: were prepared by cross-linking 6 µl of a mixture formed of AO (stock solution 20 mg/ml in PB), HRP (stock 10 mg/ml in PB) with an osmium redox hydrogel. The osmium redox hydrogel consisted of PV<sub>13</sub>-dmeOS (stock 10 mg/ml in PB) and PEGDGE (5 mg/ml freshly prepared and used within 15 min). The bi-enzyme cross-linked into the redox hydrogel was placed on the top of the graphite electrode in different ratios in % by weight (w/w).

35

Type III electrodes: was prepared using a sequential coating procedure.



Type III a - first a premixed solution 6  $\mu$ l of HRP<sub>13</sub>-dmeOs, and PEGDGE was placed on the top of the electrode. Next, the electrodes were dried for 1 hour before coating with 6  $\mu$ l of AO (see table III).

Type III b - first a solution of 6  $\mu$ l of AO was placed on the top of the electrode. After drying for 1 hour, the electrodes were coated with 6  $\mu$ l of a premixed solution of HRP, PV<sub>13</sub>-dmeOs, and PEGDGE.

Type III c- in the first step, a drop of HRP solution (6  $\mu$ l) was placed on the top of the electrode, and after its drying, a second layer containing 6  $\mu$ l of a premixed solution of AO, PVI<sub>13</sub>-dmeOs, and PEGDGE was added.

Type III d - first a premixed solution of 6  $\mu$ l of AO, PV<sub>13</sub>-dmeOs, and PEGDGE was placed on the top of the electrode. Next, electrodes were dried for 1 hour before coating 6  $\mu$ l of HRP.

If not otherwise stated, all modified electrodes were stored at 4°C for 14 h in a glass beaker and were rinsed with PB before use.

The bi-enzyme graphite electrodes were inserted as the working electrode in three electrode cell of wall jet-type placed in a single channel flow-injection system containing a manual sample injection valve (Valco Instruments Co. Inc., Houston, TX, USA) and a 50  $\mu$ l injection loop.

A peristaltic pump (Alitea AB, Stockholm, Sweden) was used to pump the carrier solution at desired flow rates through Teflon tubings (0.5 mm i.d.) to the flow cell. A potentiationstat (Zäta-Elektronik, Höör, Sweden) maintained the constant potential between the working and the reference electrode Ag/AgCl (0.1 M KCl). A platinum wire was used as the counter electrode. The response current was monitored with a single channel recorder (Model BD 111, Kipp&Zonen, Delft, The Netherlands).

Operational stability experiments were made using an Automated Sample Injection Analyser (Ismatec, Glattgurg-Zürich, Switzerland) by injecting samples of 100 µM histamine and 50 µM putrescine respectively, with a sample through-put of 30 injections/h using PB as the carrier solution at a flow rate of 0.5ml/min.

The increasing tendency of the apparent Michaelis-Menten constant with the amount of immobilised horseradish peroxidase was attributed to an increase in the thickness of the total protein loading on the electrode surface. The reducing the analytes diffusion rate in the film is effected by the influence of the protein loading. The maximum current, as well as the biosensors sensitivity trend show that the best combination is the one containing 80% by weight amine oxidase and 20% by weight horseradish peroxidase, which has been considered for the further experiments. The dynamic range for all the studied biosensors of Type I was 1 - 100 µM for both histamine and putrescine.

Different characteristics of Type I biosensors were measured and calculated for different ratios of amine oxidase AO and horseradish peroxidase HRP. The values are introduced into table I. Where  $I_{\max}$  and  $K_m^{\text{app}}$  values are estimated from Michaelis-Menten equation:

$$I = (I_{\max} \times [A]) / (K_m^{\text{app}} + [A])$$

In table I: A is analyte, S is the sensitivity, calculated as  $I_{\max}/K_m^{\text{app}}$ , C is the conversion, calculated as  $S_{\text{analyte}}/S_{\text{H}_2\text{O}_2}$  and DL is the detection limit, calculated as 3 S/N (signal- to -noise ratio).

TABLE I

Type of elec-trode (w/w)	Analyte	$K_m^{app}$ ( $\mu M$ )	$I_{max}$ ( $\mu A$ )	S ( $mA/Mcm^2$ )	C (%)	DL ( $\mu M$ )
AO 87%	Histamine	279 $\pm$ 16	1.03 $\pm$ 0.02	50.57 $\pm$ 0.82	19.0	0.16
HRP 13%	Putrescine	153 $\pm$ 15	1.96 $\pm$ 0.06	175.48 $\pm$ 1.40	66.2	0.06
	H <sub>2</sub> O <sub>2</sub>	93 $\pm$ 3	1.80 $\pm$ 0.21	265.13 $\pm$ 1.65	-	-
AO 80%	Histamine	332 $\pm$ 17	1.34 $\pm$ 0.03	55.28 $\pm$ 0.76	16.6	0.20
HRP 20%	Putrescine	228 $\pm$ 15	3.01 $\pm$ 0.07	180.84 $\pm$ 0.95	54.7	0.07
	H <sub>2</sub> O <sub>2</sub>	112 $\pm$ 8	2.07 $\pm$ 0.06	330.23 $\pm$ 1.02	-	-
AO 67%	Histamine	370 $\pm$ 22	1.30 $\pm$ 0.03	48.13 $\pm$ 0.14	14.7	0.25
HRP 33%	Putrescine	240 $\pm$ 15	3.10 $\pm$ 0.01	176.94 $\pm$ 0.87	54.2	0.70
	H <sub>2</sub> O <sub>2</sub>	153 $\pm$ 6	3.64 $\pm$ 0.04	325.90 $\pm$ 0.56	-	-
AO 50%	Histamine	437 $\pm$ 43	1.22 $\pm$ 0.04	38.24 $\pm$ 1.42	12.7	0.33
HRP 50%	Putrescine	268 $\pm$ 23	3.05 $\pm$ 0.10	155.90 $\pm$ 1.26	52.0	0.08
	H <sub>2</sub> O <sub>2</sub>	175 $\pm$ 8	3.83 $\pm$ 0.05	299.80 $\pm$ 0.65	-	-
AO 40%	Histamine	441 $\pm$ 23	1.16 $\pm$ 0.02	36.03 $\pm$ 0.75	10.9	0.34
HRP 60%	Putrescine	276 $\pm$ 22	3.69 $\pm$ 0.06	183.14 $\pm$ 1.11	55.7	0.13
	H <sub>2</sub> O <sub>2</sub>	206 $\pm$ 3	4.94 $\pm$ 0.03	328.50 $\pm$ 0.22	-	-
AO 33%	Histamine	479 $\pm$ 41	1.37 $\pm$ 0.10	39.18 $\pm$ 1.54	12.2	0.41
HRP 67%	Putrescine	287 $\pm$ 12	3.84 $\pm$ 0.06	183.28 $\pm$ 0.61	57.0	0.08
	H <sub>2</sub> O <sub>2</sub>	211 $\pm$ 18	4.95 $\pm$ 0.15	321.36 $\pm$ 1.24	-	-

- 5 Redox hydrogel based biosensors were optimised in order to determine the influence of the redox polycation and the crosslinking agent. Table II shows the obtained results.

10 If the diffusion barrier increased with the number of added components on the electrode surface, a tendency reflected in the change of the apparent Michaelis-Menten constants.  $K_m^{app}$  constant was increased with about 171% for histamine and 125% for putrescine. The introduction of the electrochemical mediator caused a considerable improvement in the bioelectrocatalytic efficiency, as can be seen from increase in the  $I_{max}$  with 262%

15

-11-

for histamine and 141% for putrescine and the sensitivity values with 33% for histamine and 7% for putrescine.

The hydrogen peroxide sensitivity remains practically unchanged. The detection limit and also the dynamic range for the studied analytes have also been improved in the case of type II electrodes.

In the table DR is the dynamic range and all the other symbols are the same as in Table I.

TABLE II

Type of electrode	Analyte	$K_m^{app}$ ( $\mu M$ )	$I_{max}$ ( $\mu A$ )	S (mA/Mcm <sup>2</sup> )	C %	DL ( $\mu M$ )	DR ( $\mu M$ )
Type I	Histamine	332 $\pm$ 17	1.34 $\pm$ 0.02	55.29 $\pm$ 0.73	16.74	0.16	1-100
	Putrescine	227 $\pm$ 16	3.01 $\pm$ 0.07	181.64 $\pm$ 1.01	55.01	0.06	1-100
	H <sub>2</sub> O <sub>2</sub>	112 $\pm$ 8	2.70 $\pm$ 0.06	330.14 $\pm$ 1.02			1-100
Type II	Histamine	901 $\pm$ 85	4.85 $\pm$ 0.41	3.874 $\pm$ 1.73	23.07	0.33	1-150
	Putrescine	512 $\pm$ 40	7.26 $\pm$ 0.53	194.11 $\pm$ 1.37	60.73	0.17	1-400
	H <sub>2</sub> O <sub>2</sub>	977 $\pm$ 92	22.8 $\pm$ 1.68	319.59 $\pm$ 1.63			1-250

The effect of the coating procedure for the type II and type III biosensors was also studied. Besides coating with a pre-mixed solutions of all four components, different possibilities of sequential coatings of the electrode surface, were also studied, see Table III. Both HRP and AO can be electrically wired to the redox polymer, and thus cause a partial short-circuit, when all components are mixed together. This was confirmed for the main substrate, putrescine, for which an increase in sensitivity of about 30 % was observed for the two layer electrodes (type III), compared to the one-layer electrodes (type II).

No considerable change was observed for the other substrate histamine, the slight decrease in sensitivity being not representative considering, the differences of about 10-15 % in

electrode preparation. Clearly, the less sensitive electrode configuration is represented by type III d type electrodes, for which the bias currents due to the wiring of AO are the most explicit. Considering the simplicity of electrode preparation and the small differences in the electrode characteristics between type II and type III electrodes, type II was chosen as optimal electrode design.

TABLE III

Type of electrode	Analyte	$K_m^{app}$ ( $\mu M$ )	$I_{max}$ ( $\mu A$ )	S (mA/Mcm <sup>2</sup> )
Type II	Histamine	901 $\pm$ 85	4.85 $\pm$ 0.41	67.65 $\pm$ 1.73
	Putrescine	512 $\pm$ 40	7.26 $\pm$ 0.53	194.24 $\pm$ 1.46
Type IIIa	Histamine	789 $\pm$ 35	3.56 $\pm$ 0.08	61.80 $\pm$ 0.68
	Putrescine	449 $\pm$ 34	7.72 $\pm$ 0.69	235.53 $\pm$ 1.60
Type IIIb	Histamine	687 $\pm$ 47	2.66 $\pm$ 0.24	53.03 $\pm$ 1.55
	Putrescine	473 $\pm$ 28	2.04 $\pm$ 0.13	59.08 $\pm$ 1.19
Type IIIc	Histamine	689 $\pm$ 33	2.17 $\pm$ 0.06	43.14 $\pm$ 0.75
	Putrescine	422 $\pm$ 35	7.83 $\pm$ 0.82	254.17 $\pm$ 1.82
Type IIId	Histamine	649 $\pm$ 19	1.90 $\pm$ 0.02	40.10 $\pm$ 0.42
	Putrescine	425 $\pm$ 24	2.14 $\pm$ 0.20	68.97 $\pm$ 1.49

The influence of various components of the redox hydrogel on the biosensor characteristics is shown in Table IV. The increasing  $K_m^{app}$  in the presence of both PVI<sub>13</sub>-dmeOs and PEGDGE demonstrated that the diffusion of the substrate was limited. This was because of the barrier formed by the mediator and/or cross-linking agent (rigidity of the redox hydrogel) on the surface of the electrode, which also resulted in an increased linear dynamic range. On the other hand, in the presence of crosslinked redox polycationic mediator (PVI<sub>13</sub>-dmeOs), the  $I_{max}$  value was 100% increased suggesting that the final reduction step of the topa cofactor on the electrode surface is the rate-limiting step in the absence of the metyldiator.

In Table IV the response characteristics of different AO biosensors. The AO, PVI<sub>13</sub>-dmeOs and PEGDGE concentrations were 5 mg/ml, 2 mg/ml and 0,5 mg/ml, respectively.

TABLE IV

Type of electrode	$K_m^{app}$ ( $\mu$ M)	$I_{max}$ (nA)	S (mA/Mcm <sup>2</sup> )	DL ( $\mu$ M)	DR ( $\mu$ M)
AO	375 $\pm$ 34	164 $\pm$ 6.5	5.99 $\pm$ 0.09	2.7	10-100
AO+PEGDGE	755 $\pm$ 38	185 $\pm$ 5.0	3.35 $\pm$ 0.05	4.5	10-150
AO+OVI <sub>13</sub> -dmeOs	770 $\pm$ 14	235 $\pm$ 2.4	4.18 $\pm$ 0.02	3.7	10-150
AO+PVI <sub>13</sub> -dmeOs+ PEGDGE	730 $\pm$ 33	360 $\pm$ 8.0	6.76 $\pm$ 0.05	2.2	10-200

## DESCRIPTION OF THE FIGURES

Figure 1: Shows a voltammogram for 100  $\mu$ M histamine using an AO - HRP modified graphite electrode (I).

Figure 2: Shows the effect of the flow rate on the response current and sample throughput of Type I biosensors.

Figure 3: Shows the relative selectivity for different amine oxidase substrates, using histamine as reference compound, recorded for Type I (white) and Type II (black) electrodes.

Figure 4: Shows the monitoring of freshness in fish samples using Type II electrodes. The total amine concentration is expressed in histamine equivalent units.

The bi-enzyme electrodes were optimised with regard to several parameters, e.g. working potential, flow rate, influence of various enzyme ratios and electrode coating procedure.

Hydrodynamic voltammograms were recorded using 100  $\mu$ M histamine as substrate and using an AO-HRP-modified type I electrodes in order to establish the optimal working potential. The voltammogram, together with the ratio between the response and the background current obtained in the same conditions, respectively, are shown in Figure 1. Although the response of the biosensor drastically increased when the applied potential was below -100mV so did the background current, which demonstrates a possible oxygen reduction interference with the biosensing process. A potential of -50 mV vs. Ag/AgCl was chosen as a compromise between the response and the background current. The background current obtained in the same condition ( $I_0$ ), and the ratio between them ( $I/I_0$ ). Conditions: electrode Type I, AO : HRP 1 : 1 (w/w), flow rate 0,5 ml/min.

15

The influence of carrier flow rate on the biosensor response for histamine was also considered for type I electrodes, the results are presented in Figure 2. The decrease in peak height with the increase in flow rate demonstrates a limitation due either to the bioconversion of the amine substrate by AO or to the reduction of  $H_2O_2$  by the direct electron transfer between HRP and the graphite electrode. According to the obtained results an optimal working flow rate was chosen to be 0.5 ml/min, as a compromise between the biosensor kinetics and its sample throughput. Conditions: injections of 100  $\mu$ M histamine, AO : HRP 1 : 1 (w/w), applied potential -50 mV vs. Ag/AgCl.

25

Type II biosensors were further characterised with regard to selectivity, response time, operational and storage stability. Figure 3 shows the relative selectivity for different AO substrates, using histamine as a reference compound, since it is a biomarker of major interest. As seen, the response for aliphatic amines is generally higher than those observed for the aromatic ones. Also, type II biosensors yielded higher sensitivities than type I ones, probably caused by better electron-transfer kinetics.

30

35

The response time of the sensor, calculated as the time elapsed between 5% and 95% of response height, was fast (less than 1 min).

5 The operational stability of the biosensor was studied both for histamine and putrescine as substrate. The response current of the bi-enzymatic enzyme electrode decreased with about 30% and 50% for histamine and putrescine, respectively. This after 10 h of continuous operation with a sample throughput of 30 injections/h. The storage stability of the electrodes was good, a decrease of only about 10% and 15% being observed for histamine and putrescine, respectively, after 10 days of storage.

15 The substrates are histamine His, cystamine Cys, tyramine Tyr, spermidine Spr, ethylenediamine EDA, agmatine Agm, putrescine Put, cadaverine Cad, Z-Ab-Z-1,4-diamino-2-butene and E-Ab-E-1,4-diamino-2-butene.

20 The optimised biosensor was considered for monitoring biogenic amines in real samples. The differentiation between the signals given by different amines is not possible, only the total amine content in a sample could be determined. Triplets of 1.0 g of fish samples were taken from fish-muscles from trobot - *Psetta maxima* - and were kept in different conditions.

25 The samples were homogenised in 10 ml PB. The homogenates were centrifuged at 13000 g for 60 min at 4°C. The supernatants were separated and immediately analysed by direct injection into the flow system. The fish-muscle samples, which had been kept both at 4°C and 25°C for 10 days, were analysed after extraction in

30 PB by direct injection in the flow system. The total amine content expressed in histamine equivalents is presented in Figure 4. The maximum accepted limit for total amine concentration in food products is 100 to 200 mg/kg samples, and a concentration of 1000 mg/kg is considered to be toxic. After 3 days of storage

35 at room temperature, the fish-samples become improper to consume, while even after 10 days of storage at 4°C there are not any major changes in the total amine concentration.



CLAIMS

1. A biosensor for the detection and/or the determination of freshness biomarkers, such as biogenic amines, comprising an electrode and a mono-enzyme system of an amine oxidase or a bi-enzyme system of an amine oxidase and a peroxidase, **characterised in** that the amine oxidase is a copper-containing amine oxidase derived from grass pea (AO, E.C. 1.4.3.6).
2. The biosensor according to claim 1, **characterised in** that the bi-enzyme system contains said copper-containing amine oxidase derived from grass pea coupled with horseradish, soybean, tobacco, sweet potato or palmtree peroxidase.
3. The biosensor according to claim 2, **characterised in** that the peroxidase is horseradish peroxidase.
4. The biosensor according to any of the preceding claims, **characterised in** that the mono-enzyme or the bi-enzyme system is crosslinked into an osmium based redox polymer.
5. The biosensor according to claim 4, **characterised in** that the osmium based redox polymer includes poly(1-vinylimidazole) complexed with  $[\text{Os}(4,4'\text{-dimethyl-bi-pyridin})_2 \text{Cl}]^{+/2+}$  and poly(etyleneglycol)diglycidyl-ether, as the crosslinking agent.
6. The biosensor according to any of the preceding claims, **characterised in** that the biosensor is of Type I, Type II or Type III type of biosensor; wherein  
  
Type I: the mono-enzyme or the bi-enzyme system is added direct on to the electrode surface; or  
  
Type II: the mono-enzyme or the bi-enzyme system is entrapped in the osmium based redox polymer added on the top of the electrode; or

Type III: the mono-enzyme or the bi-enzyme system and the osmium based redox polymer forms sequential coatings added on top of the electrode.

- 5 7. The biosensor according to claim 6, **characterised in** that the biosensor of Type III is one of Type III a, Type III b, Type III c or Type III d, wherein

10 Type III a: a second coating of the mono-enzyme is coating a dried layer of peroxidase and redox hydrogel; or

Type III b: a second coating of peroxidase and redox hydrogel is coating a dried layer of the mono-enzyme; or

15 Type III c: a second coating of the mono-enzyme entrapped in redox hydrogel is coating a dried layer of peroxidase; or

20 Type III d: a second coating of peroxidase is coating a dried layer of mono-enzyme entrapped in redox hydrogel.

- 25 8. The biosensor according to any of the preceding claims, **characterised in** that the electrode is of noble metals, such as gold, silver, platinum, palladium, or carbon/graphite-based material, such as graphite, carbon paste, vitrous carbon, carbon fibres, or conducting salts, or conducting polymers

9. The biosensor according to claim 8, **characterised in** that the electrode is made of graphite.

- 30 10. Use of the biosensor according to any of claims 1 to 9, as an analytical instrument or tool for the detection or determination of freshness biomarkers or of the content of freshness biomarkers in food, such as meat from animals or fishes, or beverages.

- 35 11. Use of the biosensor according to any of claims 1 to 9, as an analytical instrument or tool for the detection or determination of biogenic amines, preferably histamine, in body flu-

07 MARCH 2001

-18-

ids, such as blood, urine, saliva, sweat, in medical diagnoses or in the treatment of diseases.

12. Use of the biosensor according to any of claims 1 to 9,  
5 as an analytical instrument or tool for the detection or determination of biogenic amines, preferably histamine, in microdialysates or dialysates.

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number  
**WO 01/02827 A3**

- (51) International Patent Classification<sup>7</sup>: C12Q 1/26, 1/28, G01N 33/12
- (21) International Application Number: PCT/SE00/01449
- (22) International Filing Date: 6 July 2000 (06.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 9902608-0 6 July 1999 (06.07.1999) SE
- (71) Applicant (for all designated States except US): FORSKARPATENT I SYD AB [SE/SE]; Ideon, S-223 70 Lund (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): CSÖREGI, Elisabeth [SE/SE], Borgåsslingan 31, S-224 72 Lund (SE). NICULESCU, Mihaela [SE/SE]; Systervägen 9, S-221 41 Lund (SE). FRÉBORT, Ivo [CZ/CZ]; Handkeho 5, 779 00 Olomouc (CZ).
- (74) Agents: IVERSEN HASSELROT, Eva et al.; Allied Attorneys Chemical AB, Box 24107, S-104 51 Stockholm (SE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report  
— with amended claims
- (88) Date of publication of the international search report: 28 June 2001
- (48) Date of publication of this corrected version: 9 August 2001
- (15) Information about Correction: see PCT Gazette No. 32/2001 of 9 August 2001, Section II
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BIOSENSOR

(57) Abstract: The present invention relates to a biosensor for the detection and/or the determination of freshness biomarkers, such as biogenic amines (preferably histamine) in food and beverage, comprising an electrode and a mono-enzyme system, such as an amine oxidase, or a bi-enzyme system of an amine oxidase and a peroxidase. The enzymes are optionally crosslinked into an osmium based redox polymer.

WO 01/02827 A3

1/3




Figure 1

2/3




Figure 2




Figure 3

3/3




Figure 4

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:**

U.S. APPLICATIONS		STATUS (Check One)		
U.S. Application Number	U.S. Filing Date	Patented	Pending	Abandoned
PCT APPLICATIONS DESIGNATING THE U.S.				
PCT Application No.	PCT Filing Date	U.S. Serial Numbers Assigned (if any)		
PCT/SE00/01449	July 6, 2000			

**POWER OF ATTORNEY:** As named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Steven W. Allis, Reg. No. 50,532; Stephen A. Becker, Reg. No. 26,527; John G. Bisbikis, Reg. No. 37,095; Daniel Bucca, Reg. No. 42,368; Kenneth L. Cage, Reg. No. 26,151; Jennifer Chen, Reg. No. 42,404; Bernard P. Codd, Reg. No. 46,429; Lawrence T. Cullen, Reg. No. 44,489; Paul Devinsky, Reg. No. 28,553; Margaret M. Duncan, Reg. No. 30,879; Shamita De. Etienne-Cummings, Reg. No. 46,072; Ramyar M. Farid, Reg. No. 46,692; Brian E. Ferguson, Reg. No. 36,801; Michael E. Fogarty, Reg. No. 36,139; John R. Fuisz, Reg. No. 37,327; Willem F. Gadiano, Reg. No. 37,136; Keith E. George, Reg. No. 34,111; John A. Hankins, Reg. No. 32,029; Eric J. Kraus, Reg. No. 36,190; Catherine Krupka, Reg. No. 46,227; Jack Q. Lever, Reg. No. 28,149; Raphael V. Lupo, Reg. No. 28,363; Burman Y. Mathis III, Reg. No. 44,907; Michael A. Messina, Reg. No. 33,424; Dawn L. Palmer, Reg. No. 41,238; Joseph H. Paquin, Jr., Reg. No. 31,847; Scott D. Paul, Reg. No. 42,984; William D. Pegg, Reg. No. 42,988; Robert L. Price, Reg. No. 22,685; Gene Z. Robinson, Reg. No. 33,351; Brian K. Seidleck, Reg. No. 51,321; Joy Ann G. Serauskas, Reg. No. 27,952; David A. Spenard, Reg. No. 37,449; Arthur J. Steiner, Reg. No. 26,106; David L. Stewart, Reg. No. 37,578; Wesley Strickland, Reg. No. 44,363; Michael D. Switzer, Reg. No. 39,552; David M. Tennant, Reg. No. 48,362; Judith L. Toffenetti, Reg. No. 39,048; Daniel S. Trainor, Reg. No. 43,859; Kelli N. Watson, Reg. No. 47,170; Cameron K. Weiffenbach, Reg. No. 44,488; Aaron Weisstuch, Reg. No. 41,557; Edward J. Wise, Reg. No. 34,523; Jeffrey A. Woller, Reg. No. 48,041; Alexander V. Yampolsky, Reg. No. 36,324; Robert W. Zelnick, Reg. No. 36,978; and Wei-Chen Chen, admitted under 37 CFR 10.9(b), all of McDermott, Will & Emery.

Send Correspondence to:

McDERMOTT, WILL & EMERY  
600 13<sup>th</sup> Street, N.W.  
Washington, D.C. 20005-3096

Direct Telephone Calls to:

(name and telephone number)

(202) 756-8000

100 201	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Elisabeth	CSÖREGI	Elisabeth	
	Residence and Citizenship	City	State or Foreign Country	Country of Citizenship
	Lund, Sweden, Swedish	Lund	Sweden	SWEDEN
200 202	Post Office Address	Post Office Address	City	State & Zip Code/Country
	Borgåsslingan 31	SE-224 72	Lund	SWEDEN
	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Mihaela	NICULESCU	Mihaela	
300 203	Residence and Citizenship	City	State or Foreign Country	Country of Citizenship
	Lund, Sweden, Swedish	Lund	Sweden	SWEDEN Romania
	Post Office Address	Post Office Address	City	State & Zip Code/Country
	Muslkantvägen 10A	SE-224 68	Lund	SWEDEN
300 203	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Ivo FRÉBORT	FREBORT	Ivo	
	Residence and Citizenship	City	State or Foreign Country	Country of Citizenship
	Olomouc, Czech-Republic, Czech	Olomouc	Czech-Republic	CZECH-REPUBLIC
300 203	Post Office Address	Post Office Address	City	State & Zip Code/Country
	Handkeho 5	779 00	Olomouc	CZECH-REPUBLIC

I hereby declare that all statement made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.



JUL 08 2002

PATENT TRADEMARK

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §186(c) of any PCT International application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:

U.S. APPLICATIONS		STATUS (Check One)		
U.S. Application Number	U.S. Filing Date	Patented	Pending	Abandoned
PCT APPLICATIONS DESIGNATING THE U.S.				
PCT Application No.	PCT Filing Date	U.S. Serial Number Assigned (if any)		
PCT/SE0001445	July 8, 2000			

POWER OF ATTORNEY: As named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Steven W. Aika, Reg. No. 50,832; Stephen A. Becker, Reg. No. 26,527; John G. Elsbilds, Reg. No. 37,099; Daniel Buicca, Reg. No. 42,388; Kenneth L. Cager, Reg. No. 26,151; Jennifer Chen, Reg. No. 42,404; Bernard P. Codd, Reg. No. 48,428; Lawrence T. Cullen, Reg. No. 44,424; Paul Damodak, Reg. No. 28,583; Margaret M. Durman, Reg. No. 50,879; Shantia De, Elmore-Cummings, Reg. No. 8,072; Ramyar M. Farid, Reg. No. 48,852; Brian E. Ferguson, Reg. No. 36,807; Michael E. Fogarty, Reg. No. 38,133; John R. Fuzer, Reg. No. 37,327; William P. Gadiano, Reg. No. 37,136; Keith E. George, Reg. No. 34,111; John A. Hankins, Reg. No. 32,028; Eric J. Kroup, Reg. No. 39,180; Catherine Krupka, Reg. No. 48,237; Jack O. Laver, Reg. No. 26,148; Raphael V. Lugo, Reg. No. 22,353; Surman Y. Mathis III, Reg. No. 44,807; Michael A. Messing, Reg. No. 33,424; Dawn L. Palmer, Reg. No. 41,293; Joseph M. Paquin, Jr., Reg. No. 31,847; Scott D. Paul, Reg. No. 42,804; William D. Pegg, Reg. No. 42,988; Robert L. Price, Reg. No. 22,885; Gary J. Rubenstein, Reg. No. 38,331; Brian K. Sandlock, Reg. No. 51,321; Jay Ann G. Serrano, Reg. No. 27,932; David A. Sponard, Reg. No. 37,449; Arthur J. Swiner, Reg. No. 28,108; David L. Stewart, Reg. No. 37,378; Wesley Strickland, Reg. No. 44,393; Michael O. Switzer, Reg. No. 38,532; David M. Tennant, Reg. No. 48,262; Judith L. Toffenetti, Reg. No. 39,048; Daniel S. Trainor, Reg. No. 43,858; Kelli N. Watson, Reg. No. 47,170; Carraron K. Whitmanbeck, Reg. No. 44,488; Aaron Walschuch, Reg. No. 41,657; Edward J. Wise, Reg. No. 34,523; Jeffrey A. Womer, Reg. No. 48,041; Alexander V. Yampolsky, Reg. No. 36,324; Robert W. Zelnick, Reg. No. 26,878; and Wei-Chen Chen, admitted under 37 CFR 10.3(b), as of McDermott, Will & Emery.

Send Correspondence to:

McDERMOTT, WILL & EMERY  
800 13<sup>th</sup> Street, N.W.  
Washington, D.C. 20005-3098

Direct Telephone Calls to:  
(name and telephone number)

(202) 798-8000

201	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Elisabeth	CSORESI	Elisabeth	
	Residence and Citizenship	City	State or Foreign Country	Country of Citizenship
	Lund, Sweden, Swedish	Lund	Sweden	SWEDEN
202	Post Office Address	Post Office Address	City	State & Zip Code/Country
	Bandsällingen 31	SE-224 72	Lund	SWEDEN
	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Mihaila	NICULESCU	Mihaila	
203	Residence and Citizenship	City	State or Foreign Country	Country of Citizenship
	Lund, Sweden, Swedish	Lund	Sweden	SWEDEN ROMANIA
	Post Office Address	Post Office Address	City	State & Zip Code/Country
	Mihaila 10A	SE-224 68	Lund	SWEDEN
203	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Ivo FREBORT	FREBORT	Ivo	
	Residence and Citizenship	City	State or Foreign Country	Country of Citizenship
	Olomouc, Czech Republic, Czech	Olomouc	Czech Republic	CZECH REPUBLIC
203	Post Office Address	Post Office Address	City	State & Zip Code/Country
	Hradbanská 5	779 00	Olomouc	CZECH REPUBLIC

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 201:

*[Signature]*

Date 26/06-2002

Signature of Inventor 202:

*[Signature]*

Date 26/06-2002

Signature of Inventor 203:

*[Signature]*

Date 2/07-2002

# COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

(Includes Reference to PCT International Application(s))

Attorney's Docket Number

50159-026

As below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

BIOSENSOR

the specification of which:

- ☐ Is attached hereto.
- ☒ was filed as United States application Serial No. 10/019,651  
on January 2, 2002  
and was amended on January 2 and May 2, 2002 (if applicable).
- ☒ was filed as PCT international application Number PCT/SE00/01449  
on July 6, 2000  
and was amended under PCT Article 19 on March 7, 2001 (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known to me to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or Section 365(b) of any foreign and/or international application(s) for patent or inventor's certificate or Section 365(a) of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

## PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY (If PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
PCT	PCT/SE00/01449	July 6, 2000	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
SWEDEN	9902608-0	July 6, 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under 35 USC §119(e) of any United States provisional application(s) listed below.

## PRIOR PROVISIONAL APPLICATION(S):

Application Number	Filing Date